2005
A phase I clinical and pharmacokinetic study of weekly docetaxel followed by flavopiridol: promising activity in metastatic pancreatic cancer
Rathkopf D, Fornier M, Shah M, Kortmansky J, O’Reilly E, Winkelmann J, Balzano L, Kelsen D, Schwartz G. A phase I clinical and pharmacokinetic study of weekly docetaxel followed by flavopiridol: promising activity in metastatic pancreatic cancer. Journal Of Clinical Oncology 2005, 23: 4096-4096. DOI: 10.1200/jco.2005.23.16_suppl.4096.Peer-Reviewed Original Research
2004
A phase I dose finding study of weekly, sequential docetaxel (Doc) followed by flavopiridol (F) in patients with advanced solid tumors
Rathkopf D, Fornier M, Shah M, Kortmansky J, O'Reilly E, King A, Winkelmann J, Kelsen D, Olsen S, Schwartz G. A phase I dose finding study of weekly, sequential docetaxel (Doc) followed by flavopiridol (F) in patients with advanced solid tumors. Journal Of Clinical Oncology 2004, 22: 3072-3072. DOI: 10.1200/jco.2004.22.14_suppl.3072.Peer-Reviewed Original ResearchA phase I dose finding study of weekly, sequential docetaxel (Doc) followed by flavopiridol (F) in patients with advanced solid tumors
Rathkopf D, Fornier M, Shah M, Kortmansky J, O'Reilly E, King A, Winkelmann J, Kelsen D, Olsen S, Schwartz G. A phase I dose finding study of weekly, sequential docetaxel (Doc) followed by flavopiridol (F) in patients with advanced solid tumors. Journal Of Clinical Oncology 2004, 22: 3072-3072. DOI: 10.1200/jco.2004.22.90140.3072.Peer-Reviewed Original Research